Perspective
A Medical Moonshot Would Help Fix Inequality in American Healthcare
July 1, 2021
Featured Experts: Dana Goldman, PhD
Research
All Research Featured Research
White Paper
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
May 20, 2021
Featured Experts: Alison Sexton Ward, PhD, Karen Van Nuys, PhD, Darius Lakdawalla, PhD
White Paper
Prospects for Future Advances in Alzheimer’s Disease
August 18, 2020
Featured Experts: Jakub Hlávka, PhD, Dana Goldman, PhD
News
Due to Complex Barriers, the Overwhelming Majority of Alzheimer’s Patients Do Not Participate in Clinical Trials
August 17, 2020
Featured Experts: Dana Goldman, PhD, Julie Zissimopoulos, PhD, Paul Aisen, MD
Evidence Base
Overcoming Barriers to Success in Alzheimer’s Disease Clinical Trials
August 17, 2020
Featured Experts: Julie Zissimopoulos, PhD
White Paper
Key Barriers for Clinical Trials for Alzheimer’s Disease
August 17, 2020
Featured Experts: Dana Goldman, PhD, Niranjan Bose, PhD
Evidence Base
California Leads in Public Investment in Biomedical Innovation and It Is Beginning to Show Returns
July 1, 2020
Featured Experts: Dana Goldman, PhD
Journal Article
Economics of the Pharmaceutical Industry
June 2, 2018
Featured Experts: Darius Lakdawalla, PhD
News
Deaton Dispels the Magic of Randomized Controlled Trials at USC Lecture
May 1, 2017
Featured Experts: Sir Angus Deaton, PhD
Perspective
Alzheimer’s-Preventing Drugs May Already Exist – We Just Can’t Test Them
February 9, 2017
Featured Experts: Julie Zissimopoulos, PhD
News
Measuring Value in Clinical Trials: Patient Preference Doesn’t Equal Average Survival
October 24, 2016
Featured Experts: Jason Doctor, PhD
- ← Previous
- 1
- 2
- 3
- 4